RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BOCCADORO M
Collezione AO Cuneo

Items : 8

Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.

2021
AO Cuneo

Zamagni E; Nanni C; Dozza L; Carlier T; Bailly C; Tacchetti P; Versari A; Chauvie S; Gallamini A; Gamberi B; Caillot D; Patriarca F; Macro M; Boccadoro M; Garderet L; Barbato S; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Cavo M; Bodet-Milin C; Moreau P; Kraeber-Bodéré F; Zamagni E; Nanni C; Dozza L; Carlier T; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.

2020
AO Cuneo
AOU Città della Salute di Torino

Bringhen S; Boccadoro M; Castellino A; Celeghini I; Grasso M; D'Agostino M; Bonello F;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. in Bone marrow transplantation / Bone Marrow Transplant. 2017 Aug;52(8):1208-1211. doi: 10.1038/bmt.2017.99. Epub 2017 Jun 5.

2017
AO Cuneo
AOU Città della Salute di Torino

Pini M; Mordini N; Vitolo U; Boccadoro M; Aydin S; Iovino G; Passera R; Dellacasa C; Brunello L; Maffini E; Sorasio R; Zallio F; Festuccia M; Giaccone L; Busca A; Bruno B; Giaccone L; Festuccia M; Zallio F; Sorasio R; Brunello L; Maffini E; Dellacasa C; Passera R; Iovino G; Aydin S; Boccadoro M; Vitolo U; Mordini N; et alii...

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. in Leukemia / Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.

2016
AO Cuneo
AOU Città della Salute di Torino

Bruno B; Boccadoro M; Passera R; Giaccone L; Palumbo A; Omedè P; Fanin R; Boccasavia V; Brunello L; Ghione P; Ferrando F; Guarona G; Cena S; Benedetto R; Mordini N; Patriarca F; Festuccia M; Drandi D; Ferrero S; Ladetto M;